Johanna Ospel, ESOC 2021: Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial
We had the pleasure of meeting up with Dr Johanna Ospel (University Hospital, Basel, Switzerland) to discuss the findings from the ESCAPE-NA1 Trial.
The abstract entitled “Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial” was presented at the 7th European Stroke Conference, 1-3 September 2021.
Questions:
- Why is it so important to determine infarct progression rate in acute ischaemic stroke? (0:25)
- What were the aims, methodology, outcome measures and findings of the ESCAPE-NA1 study? (1:59)
- What factor might explain the inter-individual variance? (4:27)
- What questions remain unanswered and what future studies are planned? (5:57)
Disclosures: Johanna Ospel has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview filmed by Katey Gabrysch.
Filmed in coverage of ESOC 2021.
